Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 18,737 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phase I Clear all

Conditions: Relapsed/Refractory AML, AML, Adult, MDS, Refractory Myelodysplastic Syndromes
Interventions: NKX101 - CAR NK cell therapy; Biological
Lead sponsor: Nkarta, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2039
U.S. locations: 8
States / cities: Denver, Colorado • Jacksonville, Florida • Atlanta, Georgia + 5 more

Conditions: Breast Cancer, Cognitive Side Effects of Cancer Treatments, Stage I, II and III A Breast Cancer
Interventions: Questionnaires, MRI, Comet assay and Cell senescence; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Refractory Multiple Myeloma
Interventions: Noscapine HCl; Drug
Lead sponsor: Cougar Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 4
States / cities: Los Angeles, California • New York, New York

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: carmustine, cisplatin, cyclophosphamide, dexamethasone, etoposide, melphalan, paclitaxel, in vitro-treated peripheral blood stem cell transplantation; Drug · Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2002
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Solid Cancers
Interventions: Grape Seed Extract, Vitamin D; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Breast Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions: counseling intervention, educational intervention, psychosocial assessment and care; Behavioral · Other · Procedure
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Chevy Chase, Maryland • Hackensack, New Jersey + 1 more

Conditions: Healthy
Interventions: ALXN1840, Omeprazole; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: anti-thymocyte globulin, fludarabine phosphate, Melphalan, mycophenolate mofetil, tacrolimus, umbilical cord blood transplantation; Biological · Drug · Procedure
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy Volunteers
Interventions: 3 mg PF-03882845, 10 mg PF-03882845, 30 mg PF-03882845, 100 mg PF-03882845, Spironolactone; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Atopic Dermatitis
Interventions: RPT193, Placebo; Drug
Lead sponsor: RAPT Therapeutics, Inc., a member of the GSK plc group of companies; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 13
States / cities: Anniston, Alabama • Scottsdale, Arizona • San Diego, California + 10 more

Conditions: Immune System Disorder (Healthy Volunteer)
Interventions: Belumosudil mesylate, Placebo; Drug
Lead sponsor: Kadmon, a Sanofi Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Non Small Cell Lung Cancer
Interventions: Pharmacokinetic sampling - AZD9291, AZD9291 tablet dosing, Rosuvastatin, Pharmacokinetic sampling - rosuvastatin, Pharmacokinetic sampling - AZ5140 and AZ7550; Procedure · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
Interventions: Venetoclax, Rituximab, Etoposide, Vincristine Sulfate, Cyclophosphamide, Prednisone, Doxorubicin Hydrochloride; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 6
States / cities: Boston, Massachusetts • St Louis, Missouri • New York, New York + 3 more

Conditions: Deep Venous Thrombosis
Interventions: GMI-1271, Enoxaparin Sodium (Lovenox®); Drug
Lead sponsor: GlycoMimetics Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Resectable Non-Small-Cell Lung Cancer
Interventions: INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2, Gemcitabine (1000 mg/m2); Drug
Lead sponsor: Inhibrx Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2033
U.S. locations: 39
States / cities: Duarte, California • Glendale, California • La Jolla, California + 32 more

Conditions: Healthy
Interventions: TIX100, an orally available inhibitor of thioredoxin-interacting protein, Placebo; Drug
Lead sponsor: TIXiMED, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Colorectal Neoplasms, Gastrointestinal Neoplasms
Interventions: JNJ-89402638, Bevacizumab, FOLFOX, FOLFIRI; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 6
States / cities: Tucson, Arizona • Aurora, Colorado • Sarasota, Florida + 3 more

Conditions: Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Interventions: DCDT2980S, rituximab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 9
States / cities: Stanford, California • Denver, Colorado • Washington D.C., District of Columbia + 5 more

Conditions: Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
Interventions: AZD4360; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Santa Monica, California • Providence, Rhode Island • Houston, Texas

Conditions: Healthy Participants
Interventions: TAK-994; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: Multiple Myeloma, Plasma Cell Neoplasm
Interventions: Lenalidomide, Dexamethasone, Anticoagulants; Drug
Lead sponsor: PrECOG, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 16
States / cities: Scottsdale, Arizona • Atlanta, Georgia • Chicago, Illinois + 13 more

Conditions: Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor-negative, Stage IV Breast Cancer, Triple-negative Breast Carcinoma
Interventions: everolimus, eribulin mesylate, pharmacological study, laboratory biomarker analysis; Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 3
States / cities: Duarte, California • Rancho Cucamonga, California • South Pasadena, California

Conditions: Herpes Simplex
Interventions: Non-adjuvanted HSV formulation 1, Non-adjuvanted HSV formulation 2, Non-adjuvanted HSV formulation 3, HSV formulation 1 with adjuvant 1, HSV formulation 2 with adjuvant 1, HSV formulation 3 with adjuvant 1, HSV formulation 1 with adjuvant 2, HSV formulation 2 with adjuvant 2, HSV formulation 3 with adjuvant 2, Placebo, HSVTI_F1, HSVTI_F2; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 505 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 6
States / cities: Phoenix, Arizona • Wichita, Kansas • Kansas City, Missouri + 3 more

Conditions: Healthy Volunteers
Interventions: TAK-788, Placebo; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Search by objective public record fields.

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

Cognitive Changes Associated With Breast Cancer Treatment

A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma

Phase I Assay-guided Trial of Anti-inflammatory Phytochemicals in Patients With Advanced Cancer

Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions

A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults

Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer

A Single Dose Study Of Antimineralocorticoid Activity Of PF-03882845 In Healthy Volunteers

A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis

A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjects

Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer

Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas

Study to Assess Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-level Deep Venous Thrombosis (DVT)

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

A Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics of TIX100 in Healthy Subjects

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma

Study for AZD4360 in Participants With Advanced Solid Tumours

A Study of Different Forms of TAK-994 in Healthy Adults

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer

A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes

A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-788 Followed by Evaluation of the Effects of a Low-Fat Meal on TAK-788 PK and Evaluation of Relative Bioavailability of TAK-788 Capsules in Healthy Participants